GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes
Main finding · Incident PDResult — go to the resultAdjusted hazard ratio 0.91 95% CI 0.79–1.05Authors' conclusion
By addressing key limitations of earlier studies through a large-scale, active-comparator, new-user design, this study provides novel evidence of a delayed neuroprotective effect of GLP-1RAs. These findings support incorporating neurologic outcomes into long-term diabetes management and may inform therapy selection in high-risk populations.
Study context
- Population
- Patients with T2D initiating therapy, without prior antidiabetic therapy, parkinson's disease (PD) or dementiamatched 1:1
- Exposure
- GLP-1 RA initiation vs metformin initiation
- GLP-1RAn = 92,485
- Outcome
- Incident PD
Methodological detailsactive-comparator, new-user design, propensity score matched 1:1, TriNetX Global Collaborative Network
- Active-comparator, new-user design
- Propensity score matched 1:1
- TriNetX Global Collaborative Network
Main finding
As reported in the abstract
overall
Adjusted hazard ratio
0.91
95% CI 0.79–1.05
GLP-1RAvs Metformin
aHR 0.91 (95% CI 0.79–1.05)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | aHR (95% CI) | |
|---|---|---|
| Incident PD, time-stratified · between years 5 and 10 | 0.56 (0.34–0.93) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
All-cause mortality
- Mortality risk did not differ significantly
Original publication
GLP ‐ 1RAs versus metformin and Parkinson's risk in type 2 diabetes. Diabetes Obes Metab. Published 26 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →